Response to CAR T cell therapy can be explained by ecological cell dynamics and stochastic extinction eventsdoi:10.1101/717074Gregory J. KimmelFrederick L. LockePhilipp M. AltrockCold Spring Harbor Laboratory
provides T lymphocytes with Ab-type specificity and activates all the functions of an effector cell, including the production of IL-2 and the lysis of target cells9. Since then, efforts have been dedicated to produce a number of CARs designed to...
The new type of T cell therapy design is based on STAb-T cells, which, instead of relying on CARs, secrete bispecific antibodies that can also activate other T cells by targeting the proteins BCMA and CD3. In a study reported inScience Translational Medicine, the scientists showed that, whe...
CAR is composed of an extracellular domain for tumor antigen recognition, in which the variable regions of the heavy and light chains of an antibody are connected by a flexible linker to form a single-chain variable fragment (scFv), and an intracellular domain for triggering T cell activation,...
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surrounding the neoplastic foci. The intricate net...
T cell therapy CD28 4-1BB suicide gene Introduction Multiple myeloma (MM) is an almost-always incurable malignancy of plasma cells; new therapies are needed for MM.1,2 Chimeric antigen receptors (CARs) are artificial fusion proteins with antigen-recognition domains and T cell signaling domains.3...
Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising therapeutic effects on hematological malignancies. However, there are problems such as relapse during long-term follow-up and limited effect on solid tumors with thi
[60]. Additionally, Grupp et al. observed that a previously existing subset of CD19-negative tumor cell clones transformed into dominant clones following treatment with CD19 CAR-T cells, leading to CD19-negative relapse [61]. This recurrence can be explained in terms of natural selection [62...
As for other solid tumours, GD2 CAR T cell failure could be explained by the presence of immunoinhibitory signals in the tumour microenvironment, which tolerise T cells and render them dysfunctional against the targeted tumour [33]. A synergistic inhibition of metastatic disease has been achieved ...
The use of different types of common solid tumor cells to assess the effectiveness of CAR-T cells is explained by a need to explore the potentially different antitumor responses towards them. In addition, we evaluated the relevance of tumor cell line characteristics to developing resistance towards...